Merrill maintains Amgen at neutral

Merrill Lynch analyst Eric Ende maintained Amgen, Inc. at neutral after the company raised its 2006 earnings-per-share guidance by $0.15. Revenue guidance remained unchanged. Factors affecting the stock for the next 12 to 18 months include the CERA patent case, Johnson & Johnson anti-trust lawsuit and potential competition to the EPO franchise. Merrill raised its 2006 earnings-per-share estimate to $3.65 from $3.50, and increased 2007 earnings per share to $4.06 from $3.82 including option expenses. Shares of the Thousand Oaks, Calif.-based biotechnology company were up $2.23, or 3.49%, at $66.15 on volume of 21,139,527 shares versus the three-month running average of 8,641,800 shares. (Nasdaq: AMGN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.